Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance

Ibrutinib is approved in Japan for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) based on the results of global and domestic clinical studies. Following approval, we conducted an all-case post-marketing surveillance in Japanese patients with relapsed/refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Omi, Ai, Nomura, Fumi, Tsujioka, Shigeharu, Fujino, Akiko, Akizuki, Reiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635026/
https://www.ncbi.nlm.nih.gov/pubmed/35831100
http://dx.doi.org/10.3960/jslrt.22002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635026/
https://www.ncbi.nlm.nih.gov/pubmed/35831100
http://dx.doi.org/10.3960/jslrt.22002

Ejemplares similares